Pallavi Rastogi, MD
Medical Oncology · Paoli, PANPI 1538125992
Payments from drug & device makers
Across 106 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$393
- Novartis$329
- Pfizer$215
- E.r. Squibb & Sons, L.L.C.$213
- Merck$155
- Bayer$110
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,29691%
- Education$2159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $393 |
| Novartis | 14 | $329 |
| Pfizer | 7 | $215 |
| E.r. Squibb & Sons, L.L.C. | 6 | $213 |
| Merck | 8 | $155 |
| Bayer | 5 | $110 |
| Incyte Corporation | 4 | $102 |
| Bristol Myers Squibb | 5 | $100 |
| Eisai Inc. | 3 | $70 |
| Tempus AI, Inc | 3 | $70 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Johnson & Johnson | 3 | $58 |
| Gilead(2 entities) | 2 | $53 |
| Daiichi Sankyo Inc. | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 2 | $48 |
| Sobi, Inc | 2 | $44 |
| Astellas Pharma US Inc | 2 | $43 |
| Array Biopharma Inc | 2 | $37 |
| GSK | 2 | $36 |
| Fortovia Therapeutics, Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Seagen Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Pharmaessentia USA Corporation | 1 | $20 |
| Amgen | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $1 |
How this compares
$2,512 in reported general payments places this provider in the 30th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 35 | $572,481 |
| ImbruvicaIbrutinib | 30 | $532,056 |
| RevlimidLenalidomide | 18 | $300,887 |
| JakafiRuxolitinib Phosphate | 11 | $185,443 |
| XtandiEnzalutamide | 12 | $172,358 |
| EliquisApixaban | 45 | $50,067 |
| XareltoRivaroxaban | 34 | $39,639 |
| CreonLipase/Protease/Amylase | 12 | $17,020 |
| Exemestane | 27 | $5,337 |
| Anastrozole | 209 | $4,539 |
| Enoxaparin Sodium | 12 | $2,666 |
| Tamoxifen Citrate | 80 | $1,991 |
| Letrozole | 44 | $1,587 |
| Hydroxyurea | 28 | $466 |
| Acyclovir | 35 | $438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $215 | $622,54880 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $67 | $532,05630 claims |
| Bristol Myers SquibbRevlimid | $100 | $300,88718 claims |
| Incyte CorporationJakafi | $102 | $185,44311 claims |
| Astellas Pharma US IncXtandi | $43 | $172,35812 claims |
| Johnson & JohnsonXarelto | $58 | $39,63934 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $17 | $43835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Paoli
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.